patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug · protein
lutetium Lu 177 vipivotide tetraxetan
Marketedupdated 2mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for prostate cancer and 6 investigational indications.
targets
Glutamate carboxypeptidase 2
all catalysts(4)
approval · 4
News(1)
- Novartis pulls Pluvicto prostate cancer label expansion filing in the EUNovartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain f…endpoints · 2mo ago
comments(0)
5-min edit window · permanent after that